Portfolio
ImmTOR® and ImmTOR-IL™ have the potential to restore natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.
Find Out HowPioneering Precision Immune Tolerance
Our ImmTOR® platform has the potential to overcome the challenges of autoimmunity and immunogenicity.
Immunotherapies for Autoimmune Disease
Re-imagining Immunotherapy for Autoimmune Disease
The current standard of care for autoimmune disease is broad immunosuppression, which is associated with side effects and leaves patients vulnerable to serious infection and malignancies or symptom-masking treatments which do not address the underlying causes of the illness.
Our approach to autoimmune disease is highly differentiated and designed to restore natural immune system balance in vivo by co-administering IL-2 and ImmTOR® (ImmTOR-IL™) with nanoparticle-encapsulated self-antigens and avoid the need for chronic and systemic immune suppression.
Gene TherapY
Unlocking the Potential of AAV Gene Therapy
ImmTOR® has the potential to induce adeno-associated virus (AAV) vector-specific immune tolerance, reducing the severity of the body’s immune response to AAV gene therapy and enabling repeat administrations.
Currently 30-70% of patients are ineligible for gene therapy due to natural pre-existing anti-AAV antibodies. Selecta’s novel, in-licesned IgG protease, Xork, has the potential to expand access to life-saving gene therapy for patients who would otherwise be unable to receive them.
Biologic Therapy
Amplifying the Efficacy of Biologics
For many patients that require biologic therapy, the development of an immune response to the drug itself coincides with a loss of efficacy, often forcing them to discontinue treatment. When ImmTOR® is co-administered with immunogenic therapeutic biologics, it has the potential to ameliorate an immune response to the treatment, which would allow patients to continue to respond to treatment and stay on therapy longer.
Wholly-Owned Pipeline
Indication |
| Stage of Development Preclinical Phase 1 Phase 2 Phase 3 |
| Commercial Rights |
|---|---|---|---|---|
Re-imagining immunotherapy for autoimmune disease | ||||
Tolerogenic Therapies | ||||
Autoimmune liver diseases 0 | 0 | 21 | 0 |
0 |
Other autoimmune diseases 0 | 0 | 21 | 0 |
0 |
Amplifying the efficacy of biologic therapies | ||||
Biologic Therapies | ||||
IgA nephropathy (IgAN) 0 | 0 | 22 | 0 |
0 |
Partnered
Indication | Antigen | Stage of Development Preclinical Phase 1 Phase 2 Phase 3 |
| Commercial Rights |
|---|---|---|---|---|
Unlocking the potential of Gene Therapy | ||||
Gene Therapies | ||||
Pompe Disease 0 | IgG Protease (Xork) 0 | 20 SEL-018 | 0 |
0 |
Duchenne muscular dystrophy (DMD) 0 | Undisclosed 0 | 20 | 0 |
0 |
Limb-girdle muscular dystrophy (LGMD) 0 | Undisclosed 0 | 20 | 0 |
0 |
Two indications for lysosomal storage disorder 0 | Undisclosed 0 | 20 | 0 |
0 |
Amplifying the efficacy of biologic therapies | ||||
Biologic Therapies | ||||
Chronic Refractory Gout 0 | Pegadricase 0 | 90 SEL-212 | 0 |
0 |
Our Platform
ImmTOR® and ImmTOR-IL™: Precision Immune Tolerance Platform
ImmTOR® and ImmTOR-IL™ comprise an immune tolerance platform designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. This platform has the potential to restore natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.
Partner with us
Learn more about partnership opportunities
Selecta licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout, to Sobi in mid-2020. Selecta has also partnered with leading gene therapy companies, including Takeda, Sarepta Therapeutics and AskBio to evaluate the potential of ImmTOR® to enable redosing of life-saving gene therapy. Selecta is also looking for partnerships to unlock the potential of its proprietary IgG protease, Xork, for the mitigation of pre-existing anti-AAV antibodies.
